HOME >> BIOLOGY >> NEWS
Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps

Investigational Drug Halts New Polyp Formation; Appears Well-Tolerated For Extended Use

HORSHAM, PA (May 20, 1998) -- Cell Pathways, Inc. today announced results from an open-label extension study of the company's lead investigational compound, FGN-1--(exisulind), in patients with Familial Adenomatous Polyposis (FAP; also known as Adenomatous Polyposis Coli, APC). Eighteen patients continuing on FGN-1 for as long as 18 months following the completion of a six month Phase I/II dose-ranging, safety and efficacy trial tolerated drug treatment well. The progressive increase in precancerous polyps that normally occurs in this patient population appeared to be arrested by the treatment. In addition, existing polyps in the FGN-1 treated patients appeared to decrease in size or remain stable over time.

The extension study results will be presented today at the American Gastroenterological Association meeting in New Orleans, Louisiana by clinical investigator, Rosalind van Stolk, M.D. of the Cleveland Clinic Foundation.

"FAP patients have historically experienced, on average, a significant increase in the number of precancerous polyps that develop in their rectum over a 12 month period," said Dr. van Stolk. "In contrast, we observed that new polyp formation halted in all patients receiving effective doses of FGN-1 for periods of 12 to 24 months, and in 16/18 patients, small polyps (6 mm or less) tended to regress in size while larger polyps remained stable."

"We are very encouraged by these results, which show a strong trend that supports FGN-1's ability to prevent the normal progression of disease in patients with FAP," said Rifat Pamukcu, M.D., chief scientific officer and senior vice president of research and development at Cell Pathways. "Left untreated, FAP patients invariably develop colon cancer." He noted that a randomized, placebo-controlled Phase III trial of FGN-1 i
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
20-May-1998


Page: 1 2 3

Related biology news :

1. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
2. Pathways of emotion from cortex to peripheral organs
3. Cell Pathways CP461 demonstrates multiple anti-cancer activities
4. Cell Pathways scientists describe mechanism by which SAANDS compounds trigger programmed death in cancerous and precancerous cells
5. Pitt Researchers Find Way To Block Cellular Growth Pathways And Inhibit Tumor Growth
6. Discovery Of Genetic Pathways May Provide New Ways To Combat Candida Infections
7. Reports of "weird life" almost stranger than fiction
8. Reports from special environmental health issue explore links to autoimmune diseases - diabetes, lupus, multiple scleroris and arthritis
9. Osiris Therapeutics Reports Key Findings in SCIENCE Verifying Existence of Adult Stem Cells
10. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
11. New England Journal Of Medicine Reports Calcium Supplements Help Prevent Polyp Recurrence; DMS Led Study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/2/2018)... ... August 02, 2018 , ... RxS LLC ... biotech companies, today announced that Mark Jara, principal of the organization, has been ... life sciences industry. Individuals named to PharmaVOICE 100 are leaders who drive the ...
(Date:8/1/2018)... ... August 01, 2018 , ... RURO, Inc., ... Limfinity® version 7.1. Limfinity® is the software framework that all of RURO’s products ... for both current users and the future of RURO’s laboratory software portfolio. , ...
(Date:8/1/2018)... ... August 01, 2018 , ... Clinical Training ... MA's and Administrative staff. , This full day course is an interactive day ... will expose your staff to regenerative medicine procedures and processing techniques, and facility ...
Breaking Biology News(10 mins):
(Date:8/7/2018)... , ... August 06, 2018 , ... ... and diagnostics companies, announces the placement of Dr. Paul Harney as President, North ... North America growth strategy and enhancing client satisfaction. He was also named to ...
(Date:7/31/2018)... ... July 31, 2018 , ... Leading regenerative veterinary medicine ... extracting and using adipose tissue-derived stem cells to treat or prevent inflammation at ... patent covers Canada specifically, VetStem has been issued similar patents that cover the ...
(Date:7/27/2018)... ... July 27, 2018 , ... ... Group (BRAG®) and representatives of the Biotechnology Innovation Organization (BIO) met with ... white paper, “Proposal for a Toxic Substances Control Act (TSCA) Inventory Representation ...
(Date:7/25/2018)... GENEVA, Wis. (PRWEB) , ... July 25, 2018 ... ... impact of a biofield energy treated proprietary nutraceutical to combat inflammation and autoimmune ... as well as, immune function response. The following data was reported:, ...
Breaking Biology Technology:
Cached News: